Alexion has boosted AstraZeneca’s rare disease expertise while the company has experienced success in oncology and COVID-19.
Through its Alexion subsidiary, AstraZeneca is acquiring Lexington, Mass.-based LogicBio Therapeutics in a deal worth $68 million. The deal bolsters AstraZeneca’s efforts in genomics and rare diseases.
While the economy expands and contracts, the biopharma industry follows, and many life science companies are announcing both layoffs and expansions.
Pharmaceutical powerhouse AstraZeneca appears to have taken an interest in the company’s London-based partner Mereo BioPharma and may be considering a buyout, according to circulating speculations first reported by The Times UK.